Natus Medical (NASDAQ:BABY) released its quarterly earnings results on Wednesday. The medical equipment provider reported $0.42 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.54 by ($0.12), Bloomberg Earnings reports. The company had revenue of $131.40 million during the quarter, compared to analyst estimates of $131.38 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The business’s revenue was up 22.0% compared to the same quarter last year. During the same period last year, the firm earned $0.51 earnings per share. Natus Medical updated its Q1 guidance to $0.23-0.24 EPS.
Shares of Natus Medical (BABY) opened at $30.80 on Thursday. Natus Medical has a 1 year low of $28.00 and a 1 year high of $43.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36. The company has a market capitalization of $954.88, a price-to-earnings ratio of 19.77 and a beta of 0.56.
A number of equities research analysts have recently commented on BABY shares. BidaskClub downgraded Natus Medical from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 6th. Zacks Investment Research downgraded Natus Medical from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 11th. Benchmark reaffirmed a “buy” rating and issued a $49.00 price objective (down previously from $55.00) on shares of Natus Medical in a research report on Tuesday, January 16th. Finally, William Blair downgraded Natus Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $47.00.
Hedge funds have recently bought and sold shares of the business. Eqis Capital Management Inc. grew its position in Natus Medical by 25.0% during the third quarter. Eqis Capital Management Inc. now owns 16,740 shares of the medical equipment provider’s stock valued at $628,000 after acquiring an additional 3,353 shares during the period. Capital Management Associates NY purchased a new stake in Natus Medical during the third quarter valued at about $412,000. JPMorgan Chase & Co. grew its position in Natus Medical by 13.4% during the third quarter. JPMorgan Chase & Co. now owns 37,767 shares of the medical equipment provider’s stock valued at $1,411,000 after acquiring an additional 4,457 shares during the period. Wells Fargo & Company MN grew its position in Natus Medical by 24.7% during the third quarter. Wells Fargo & Company MN now owns 99,741 shares of the medical equipment provider’s stock valued at $3,740,000 after acquiring an additional 19,726 shares during the period. Finally, Eagle Asset Management Inc. lifted its stake in shares of Natus Medical by 18.8% during the third quarter. Eagle Asset Management Inc. now owns 499,376 shares of the medical equipment provider’s stock worth $19,076,000 after purchasing an additional 79,170 shares in the last quarter. 93.91% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2018/02/08/natus-medical-baby-posts-earnings-results-misses-estimates-by-0-12-eps.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.